Compare GPMT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | IMA |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 66.3M |
| IPO Year | 2017 | 2021 |
| Metric | GPMT | IMA |
|---|---|---|
| Price | $0.94 | $4.86 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 298.8K | 13.9K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | ★ 73.58 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $3.94 |
| 52 Week High | $3.03 | $9.10 |
| Indicator | GPMT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 26.29 | 36.52 |
| Support Level | N/A | $4.73 |
| Resistance Level | $1.56 | $6.13 |
| Average True Range (ATR) | 0.05 | 0.32 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 3.49 | 26.67 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.